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Abstract 
Purpose: To evaluate in vivo H. pylori clearance efficacy of formulated mucoadhesive microspheres of 
amoxicillin trihydrate and clarithromycin.  
Methods: Amoxicillin trihydrate and clarithromycin mucoadhesive microspheres were prepared by 
solvent evaporation method using Carbopol 974P, HPMC K4M and Eudragit RS 100. In vivo clearance 
efficacy of the microspheres was evaluated in a Wistar rat model after induction of H. pylori infection. 
Amoxicillin and clarithromycin-loaded microspheres were administered twice daily for three days. H. 
Pylori clearance was evaluated by assessing colony count.  
Results: Treatment with plain drug solution (90 mg/kg amoxicillin and 45 mg/kg clarithromycin) resulted 
in a colony count of log 1.25 ± 0.56 CFU and clearance rate of 60 %, while mucoadhesive 
microspheres-loaded dose of 45 mg/kg amoxicillin and 22.5 mg/kg clarithromycin resulted in complete 
(100 %) eradication of H. pylori infection.  
Conclusion: The developed mucoadhesive amoxicillin/clarithromycin microspheres can potentially be 
used to effectively eradicate H. pylori infection. 
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Colonization of  gastric  mucosa  by  
Helicobacter pylori is considered to be the  cause  
of chronic gastritis,  a strong risk  factor for peptic 
ulcer disease and gastric  cancer [1,2]. 
Amoxycillin trihydrate and clarithromycin 
combinations are the standard first-line H. pylori 
eradication treatment recommended by the 
American College of Gastroenterology (ACG) [3], 
the Maastricht III Consensus Conference [4], the 
Asia-Pacific Consensus Guidelines (APC) [5] and 
more recently, Maastricht IV/Florence 
Consensus Report [6].   
 
Over the last decade, it has been widely reported 
that the success of H. pylori eradication 
treatment is falling [7]. Incomplete eradication of 
H. pylori is mainly due to the short residence time 
of antimicrobial agents in the stomach so that 
effective antimicrobial concentration cannot be 
achieved in the gastric mucous layer or epithelial 
cell surfaces where H. pylori exists [8,9].  
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Considering the above facts, we have recently 
formulated mucoadhesive microspheres of 
amoxicillin trihydrate and clarithromycin by using 
carbopol 974P, HPMC K4M and Eudragit RS 100 
to achieve the mucoadhesive, extended/ 
controlled release property and in vitro studies 
were carried out in order to select the best 
formulation [10-13].   H. pylori colonizes the 
stomach where the pH is acidic. In acidic pH, 
however, Carbopol 974P does not dissociate 
completely and also forms a less viscous gel, 
which significantly affect its release property. To 
optimize its extended/controlled release property 
and mucoadhesiveness, a combination of 
carbopol 974P and HPMC K4M was used to 
prepare mucoadhesive microspheres in the 
present study. The gelling nature of HPMC K4M 
is not affected by pH of the environment due to 
its non-ionic nature. Eudragit RS 100 was used 
as matrix polymer to disperse the mucoadhesive 
polymers and also because of its mucoadhesive 
property.  
 
The objective of the present work was to prepare 
and evaluate in vivo H. pylori clearance effect of 
mucoadhesive microspheres of amoxicillin and 
clarithromycin with the aid of Eudragit RS, 






Six week-old male Wistar rats, weighing 180 to 
220 g, were used to evaluate in vivo efficacy of 
the prepared microspheres. Amoxicillin trihydrate 
and clarithromycin were obtained as gifts from 
Macleods Pharmaceuticals Ltd, Mumbai, India.  
All the excipients were of pharmacopoeial grade 
and other chemicals used were of analytical 
grade.  
 
Preparation of culture  
 
Brucella chocolate agar media were used for in 
vivo studies [14]. Brucella chocolate agar media 
was prepared by sterilizing readymade media 
after dissolving in distilled water followed by 
addition of 10 – 20 % freshly collected sheep 
blood. Vancomycin (10 mg/L), amphoterecin B (4 
mg/L), polymyxin B sulfate (2500 IU/L) and 
trimethoprim (5 mg/L) were added to this media. 
Human biopsy sample, which were collected 
from gastric ulcer patient with consent at Krishna 
hospital, Bhavani, India. The presence of H. 
pylori bacteria in biopsy was confirmed by 
modified Gram staining and positive urease tests 
[14]. The biopsy sample was swabbed on 
Brucella chocolate agar media culture plates. 
Plates were incubated in a candle jar at 37 °C 
under microaerophilic environment. Pad of cotton 
soaked with water were kept in the candle jar to 
maintain 90-100% humidity. The plates were 
examined after 72 hrs to see the colony growth. 
The organism was identified on the basis of 
modified Gram staining and urease tests. The 
colonies were found to be translucent and gray 
with size range of 0.5 -1 µm. The bacteria were 
then subcultured in Brucella broth medium.  
 
Induction of H. pylori infection in animals 
 
The in vivo study was performed in Wistar rats. 
The protocol of the experiment was approved by 
the Institutional Animal Ethical Committee as per 
the guidance of the Committee for the Purpose of 
Control and Supervision of Experiments on 
Animals (CPCSEA), Ministry of Social Justice 
and Empowerment, Government of India 
(Proposal no. 01PH10JAN10) and the 
International Guidelines for Handling of 
Laboratory Animals [15]. The number of bacteria 
was determined as 1 optical density (OD) unit 
corresponding to 109 colony-forming unit 
(CFU)/mL bacteria at 600 nm in a Shimadzu 
UV/Visible spectrophotometer. H. pylori infection 
in animal model was  established according to 
Qian’s method [16]. The wistar rats were 
deprived of food for 24 hrs before and 4 hrs after 
H. pylori inoculation, but were otherwise afforded 
free access to food and tap water. 0.3 mL of 
broth containing 109 CFU/ml of H. pylori was 
inoculated into the stomach by intragastric 
gavage using a sterile gastric canula (6-week-old 
male Wistar rats, weight 180 to 220 grams). 
Then, the rats were fed for 4 weeks. The rats 
were kept with proper maintenance of 
temperature (20 to 25 °C), relative humidity 
(55%), and light/dark cycle (12 h/12 h). Four 





H. Pylori infectious animals were randomly 
divided in different groups (each group consists 
of 5 wistar rats) and different formulations were 
administered twice daily for three consecutive 
days as per the following dosing schedule. 
 
The animals in group 1 were treated with sterile 
water (control group). Group 2 animals were 
treated with solution containing both drugs, dose 
equivalent to 22.5mg/kg amoxicillin and 11.25 
mg/kg clarithromycin. Group 3 animals were 
treated with solution containing both drugs, dose 
equivalent to 45 mg/kg amoxicillin and 22.5 
mg/kg clarithromycin. Group 4 animals were 
treated with a solution containing both drugs at a 
dose equivalent to 90 mg/kg amoxicillin and 45 
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mg/kg clarithromycin. Group 5 animals were 
treated with mucoadhesive microspheres, 
containing both drugs (mixture of amoxicillin 
trihydrate loaded and clarithromycin loaded) 
dose equivalent to 22.5 mg/kg amoxicillin and 
11.25 mg/kg clarithromycin. Group 6 animals 
were treated with mucoadhesive microspheres, 
containing both drugs (mixture of amoxicillin 
trihydrate-loaded and clarithromycin-loaded) at a 
dose equivalent to 45 mg/kg amoxicillin and 22.5 
mg/kg clarithromycin. Group 7 animals were 
treated with mucoadhesive microspheres, 
containing both drugs (mixture of amoxicillin 
trihydrate-loaded and clarithromycin-loaded) at a 
dose equivalent to 90 mg/kg amoxicillin and 45 
mg/kg clarithromycin.   
 
H. pylori eradication confirmation 
 
One day after the administration of the final dose 
the rats were sacrificed with ether anesthesia 
and stomachs were excised. Stomach was 
homogenized in homogenizer with 3 mL of 
Brucella broth. Serial dilutions were made and 
aliquots (100 µL) of the dilutions were applied to 
Brucella agar plates. The plates were incubated 
at 37 oC under microaerophilic atmosphere for 72 
hrs under the microaerophilic condition in a 
candle jar. The viable cell counts for each 
stomach were calculated by counting the number 
of colonies on agar plates [14]. The colonies 
were identified for H. pylori by morphology and 
urease test. The number of colonies per plates 





The results were expressed as mean ± standard 
error (SE). Differences between the control and 
drug-loaded formulation treatment groups were 
statistically analyzed by ANOVA, followed by 
Dunnet’s multiple comparison test, as post-test 
(n = 5). Statistical significant differences between 
groups were defined as p < 0.05. Calculations 
were performed with Graph Pad Instat software 
(Graph Pad Software Inc, San Diego, USA). 
 
RESULTS   
 
In vivo clearance after multiple administrations of 
various formulations containing the combination 
of amoxicillin trihydrate and clarithromycin in 
under-fed conditions are presented in Table 1. 
The mean bacterial count (log colony forming 
units; log CFU) of the control group, which given 
only sterile water was log 8.55 ± 0.46 CFU. The 
mean bacterial count after oral administration of 
plain drugs decreased upon increasing the drug 
dose but complete eradication was not achieved 
even with the highest dose (90 mg/kg amoxicillin 
and 45 mg/kg clarithromycin). 
 
Treatment with a plain drug solution in a dose of 
22.5 mg/kg amoxicillin and 11.25 mg/kg 
clarithromycin gave a mean bacterial count of log 
4.65 ± 0.93 CFU and clearance rate of 40 %. 
Treatment with plain drug solution in a dose of 45 
mg/kg amoxicillin and 22.5 mg/kg clarithromycin 
gave a mean bacterial count of log 2.34 ± 0.88 
CFU and clearance rate of 60 %. A higher plain 
drug dose (90 mg/kg amoxicillin and 45mg/kg 
clarithromycin) resulted in a colony count of log 
1.25 ± 0.56 CFU and clearance rate of 60 %. 
Incomplete clearance of drug solutions might be 
due to the unavailability of 100% drug due short 
residence time of drugs in the stomach and the 
low concentration of the drugs reaching the 
bacteria under the gastric mucus layer. 
 
Mean bacterial colony count after oral 
administration of microspheres containing dose 
equivalent to 22.5 mg/kg amoxicillin and 11.5 
mg/kg clarithromycin was log 1.04 ± 0.29 CFU. In 
the case of microspheres containing dose 
equivalent to 45 mg/kg amoxicillin and 22.5 
mg/kg clarithromycin and 90 mg/kg amoxicillin 
and 45mg/kg clarithromycin, bacterial colony was 
not detected. It means treatment with 
mucoadhesive microspheres loaded drug dose of 
45 mg/kg amoxicillin and 22.5 mg/kg clarithro-
mycin or higher resulted in complete eradication 
of H. pylori infection and thus the mucoadhesive 
microspheres were found to be effective in the 




The rationale for developing and evaluating 
mucoadhesive microspheres was the need of a 
carrier system which could deliver the drug to the 
desired site of action in therapeutic 
concentrations over a prolonged period of time. 
In order to improve the efficacy of the anti H. 
pylori agents, localized delivery in the stomach 
was proposed. A combination approach, i.e., 
mucoadhesive and extended/controlled drug 
delivery system, was explored for the effective 
and improved treatment of H. pylori infection in 
the present study. Mucoadhesive drug delivery 
systems thus provide sustained drug release by 
localizing drug in the mucosal region where the 
bacteria reside [17]. This would also increase the 
antibiotic concentration in the luminal region of 
the stomach by promoting the diffusion of the 
antibiotics in the epithelial cell layer and thus 
would be effective in inhibiting the growth of 
bacteria in that region [8].  
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aCFU = colony forming unit, ND = not detected (CFU ≤ 1.00). Values are shown as mean ± SE (n = 5). Values are means ± 
SE, *p < 0.05, **p < 0.01 (compared to control). 
 
Up to 100 % H. pylori clearance rate was 
achieved. Mucoadhesive microspheres gave 
better and higher H. pylori eradication rates than 
plain drug solutions. Incomplete eradication of H. 
pylori might be the short residence time of the 
plain drugs in the gastric mucosa of animals and 
possible degradation of drugs in the acidic 
conditions in the stomach which was reported 
earlier [8,9,17]. This clearly confirms the 
hypothesis that encapsulation of drugs in the 
mucoadhesive microspheres is necessary to 
protect the drug in the acidic environment and 
also to increase their retention in the stomach for 
prolonged duration, which gives the highest 
efficacy in eradication of H. pylori infection.  
It seems from the results of the in vivo bacterial 
clearance study that, unlike the plain drug, 
mucoadhesive microspheres are plug and seal 
the ulcer area, retain in the stomach for 
prolonged duration, release the drug slowly, and 
also preventing the entire drug from being 
exposed to the acidic media, thereby producing 
better H. pylori clearance. The use of the 
mucoadhesive microspheres can enhance 
stomach-specific delivery, increase gastric 
residence time, decrease diffusional distance, 





This study demonstrates that mucoadhesive 
microspheres of amoxicillin/clarithromycin, unlike 
the solution mixture of the plain drugs, is capable 
of achieving complete clearance of H. pylori 
infection and therefore would be suitable for the 
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